Werewolf Therapeutics (NASDAQ:HOWL) Rating Lowered to Sell at Wall Street Zen

Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Price Performance

HOWL opened at $0.68 on Friday. The firm has a market cap of $33.05 million, a price-to-earnings ratio of -0.55 and a beta of 0.41. Werewolf Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $2.38. The company’s 50-day moving average price is $0.81 and its 200 day moving average price is $0.85.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Research analysts anticipate that Werewolf Therapeutics will post -1.29 earnings per share for the current year.

Insider Activity at Werewolf Therapeutics

In other news, Director Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $0.63, for a total transaction of $49,824.18. Following the sale, the director owned 1,578,749 shares of the company’s stock, valued at approximately $994,611.87. The trade was a 4.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 581,111 shares of company stock valued at $417,052 in the last quarter. 23.60% of the stock is currently owned by company insiders.

Institutional Trading of Werewolf Therapeutics

Several large investors have recently added to or reduced their stakes in HOWL. Bank of America Corp DE raised its stake in Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after purchasing an additional 221,766 shares during the period. Jane Street Group LLC bought a new stake in shares of Werewolf Therapeutics during the second quarter valued at about $409,000. Finally, Citadel Advisors LLC bought a new stake in shares of Werewolf Therapeutics during the third quarter valued at about $304,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.